Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Neoplasms, Sarcopenia
Phase NA
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the comparative effectiveness of a multi-modal facility-based rehabilitation program (therapist-led resistance exercise and relaxation training) versus a self-directed home-based resistance exercise program in post-treatment breast cancer survivors. Participants in both intervention groups will complete a 16-week program consisting of two exercise sessions per week.The multimodal, therapist-led approach is hypothesized to result in superior improvements in physical performance and quality of life outcomes compared to self-directed home exercise

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Multimodal Resistance and Relaxation Training — A 16-week multimodal program consisting of resistance exercise and relaxation training. Participants undergo two sessions per week: one weekly session is conducted under the supervision of a physical therapist at Taipei Tzu Chi Hospital, and one weekly session is self-directed and performed by the participant in a home setting. The resistance exercise portion utilizes progressive elastic band training
  • Behavioral: Home-Based Resistance Exercise Training — A 16-week self-directed resistance exercise program. The intervention consists of two sessions per week performed independently by the participant in a home setting. The exercise regimen utilizes progressive elastic band training and is conducted without direct therapist supervision

Primary Outcomes

  • Change from Baseline in Skeletal Muscle Mass Index (SMI) (16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-05
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Valeria Chiu
Contact Information
Study Contact:
Valeria Chiu
+886266289779
haydenbell28@gmail.com
Valeria Chiu
+886266289779
haydenbell28@gmail.com
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Interventions
  • Behavioral: Multimodal Resistance and Relaxation Training — A 16-week multimodal program consisting of resistance exercise and relaxation training. Participants undergo two sessions per week: one weekly session is conducted under the supervision of a physical therapist at Taipei Tzu Chi Hospital, and one weekly session is self-directed and performed by the participant in a home setting. The resistance exercise portion utilizes progressive elastic band training
  • Behavioral: Home-Based Resistance Exercise Training — A 16-week self-directed resistance exercise program. The intervention consists of two sessions per week performed independently by the participant in a home setting. The exercise regimen utilizes progressive elastic band training and is conducted without direct therapist supervision
Study Locations (1 sites)
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Xindian Dist 231 Taiwan
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed primary breast cancer * Stage I-III non-metastatic breast cancer following lumpectomy or mastectomy * Completed adjuvant chemotherapy (with or without radiotherapy) * Age ≥ 18 years * Able to understand and follow the study protocol * Willingness to attend facility-based exercise training. Exclusion Criteria: * Metastatic (Stage IV) breast cancer * Morbid obesity (BMI \> 40 kg/m²) * Uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 99 mmHg) * Presence of implantable medical devices (e.g., pacemakers, nerve stimulators) * Presence of metallic surgical implants (e.g., total hip or knee replacements) that interfere with assessment devices * Contraindications for resistance training (e.g., acute infectious disease, severe cardiac disease, severe respiratory insufficiency) * Concurrent malignant diseases * Current participation in intense systematic exercise training (defined as at least 1 hour, twice per week) * Previous participation in an exercise intervention clinical trial.
Conditions Bipolar Disorder (BD)
Phase NA
Enrollment 212
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Bipolar depression is a long-lasting and disabling condition, and many people continue to experience depressive symptoms despite standard treatments. Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation that uses a very small electrical current applied through the scalp and has shown promise as a treatment for depression. This study aims to find out whether a home-based tDCS device is effective and safe in reducing symptoms of bipolar depression when compared with a placebo (sham) treatment. The study will also look at how acceptable the treatment is to participants and how well people are able to use the device at home. Who can participate? Adult patients aged 18 years and over who have a diagnosis of bipolar disorder and are currently experiencing a depressive episode. What does the study involve? Participants must meet specific eligibility criteria, which will be assessed by the research team. People who do not meet the study criteria or for whom tDCS is not suitable will not be able to take part. Participants will be randomly assigned to receive either active tDCS or a placebo (sham) treatment. Neither the participant nor the researchers assessing outcomes will know which treatment has been assigned. Participants will use a study device at home over a defined treatment period and will complete a series of assessments at set time points. These include clinician-rated interviews and self-reported questionnaires about mood and well-being. Device use and adherence data will be collected electronically. Participants will also be monitored for any side effects throughout their involvement in the study. Although the study is multi-site, participation is primarily remote, with most study activities completed from the participant's home. What are the possible benefits and risks of participating? Participants may experience an improvement in depressive symptoms. Information gained from this study may help improve future treatments for bipolar depression. tDCS is generally well tolerated. Possible side effects include mild and temporary sensations such as tingling, itching, headache, or skin irritation at the electrode sites. All participants will be monitored for adverse events, and appropriate support will be available if needed. Where is the study run from? The study is run from King's College London in collaboration with NHS research sites across the UK. When is the study starting and how long is it expected to run for? April 2026 to October 2027 Who is funding the study? The National Institute for Health and Care Research (NIHR), UK. Who is the main contact? Professor Cynthia Fu, the Chief Investigator at King's College London, cynthia.fu@kcl.ac.uk

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Flow FL-100 tDCS headset — The Flow FL-100 tDCS device is an adjustable headset with the electrodes built in. It delivers low-intensity direct current through scalp electrodes, modulating cortical excitability in the dorsolateral prefrontal cortex (DLPFC). The device is portable and commercially available.

Primary Outcomes

  • To determine clinical efficacy of a 10-week course of home-based tDCS for bipolar depression in terms of depressive symptoms as measured by clinician-rated MADRS score in active and sham treatment arms at week 10 (From randomisation to the end of treatment at 10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-24
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 212 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: King's College London
Collaborators: South London and Maudsley NHS Foundation Trust
Contact Information
Study Contact:
Professor Cynthia Fu
0207848832
cynthia.fu@kcl.ac.uk
Oluwatofunmi Olaniyan
+44 20 7848 8326
oluwatofunmi.olaniyan@kcl.ac.uk
South London and Maudsley NHS Foundation Trust
Interventions
  • Device: Flow FL-100 tDCS headset — The Flow FL-100 tDCS device is an adjustable headset with the electrodes built in. It delivers low-intensity direct current through scalp electrodes, modulating cortical excitability in the dorsolateral prefrontal cortex (DLPFC). The device is portable and commercially available.
Study Locations (1 sites)
South London and Maudsley NHS Foundation Trust, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or over. 2. Diagnosis bipolar disorder in a current depressive episode based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al.,1998). 3. Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS (Montgomery and Åsberg, 1979). 4. Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment. 5. Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment. 6. Being under care of GP. 7. Agreeable for GP to be regularly informed by research team about participation. 8. Able to provide written, informed consent. Exclusion Criteria: 1. Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011). 2. Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM criteria as assessed in MINI (Sheehan et al., 1998). 3. Having a Young Mania Rating Scale (Young et al., 1978) score of 20 or more. 4. Current daily use of medications that affect cortical excitability (e.g. benzodiazepines). 5. Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of \> 8 in Alcohol use disorders identification test consumption (AUDITC) (Khadlesari et al., 2017; NICE, 2023). 6. History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), other brain stimulation, or psychosurgery for depression. 7. History of esketamine / ketamine for treatment of depression. 8. Medical disorder that may mimic mood disorder (e.g. hormonal disorder). 9. History of myocardial infarction, coronary artery bypass graft (CABG), coronary heart failure (CHF), or history of other cardiac issues. 10. Have cognitive impairment (e.g. dementia). 11. History of a neurological disorder (e.g., cerebrovascular events, stroke, structural lesion, epilepsy, seizures, Parkinson's disease). 12. History of migraines or intractable headaches. 13. Implant in brain, neurocranial defect or active implantable medical device. 14. Shrapnel or any ferromagnetic material in head. 15. If female and of child-bearing potential, currently pregnant or planning to become pregnant during the study 16. Concurrent enrolment in another interventional study.
Conditions Breast Cancer
Phase NA
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled experimental study aims to evaluate the effect of mindfulness-based breathing exercises on symptom management and salivary cortisol levels in breast cancer patients receiving chemotherapy. The study population will consist of breast cancer patients undergoing chemotherapy treatment in the Oncology Department of Fırat University Hospital. A total of 72 patients who meet the inclusion criteria and volunteer to participate will be included in the study, with 36 patients in the experimental group and 36 in the control group. Data will be collected using the Personal Information Form and the Edmonton Symptom Assessment Scale. The findings of this study are expected to provide evidence regarding the effectiveness of mindfulness-based breathing exercises in improving symptom management and reducing stress levels in breast cancer patients receiving chemotherapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mindfulness-Based Breathing Exercise — Mindfulness-based breathing exercises focusing attention on breathing to promote awareness and support symptom management in breast cancer patients receiving chemotherapy.

Primary Outcomes

  • Symptom Severity (Baseline and after the intervention period (e.g., 8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-10
Completion: 2026-08-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Firat University
Contact Information
Study Contact:
Gül DURAL, pHD
04242370000
gulkaya@firat.edu.tr
Gül DURAL
Gül DURAL, pHD
Gül DURAL
Interventions
  • Behavioral: Mindfulness-Based Breathing Exercise — Mindfulness-based breathing exercises focusing attention on breathing to promote awareness and support symptom management in breast cancer patients receiving chemotherapy.
Study Locations (1 sites)
Gül DURAL, Elâzığ, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being over 18 years of age * Knowing their diagnosis * Receiving chemotherapy for the first time due to a breast cancer diagnosis * Having breast cancer stages I, II, or III (stage 4 patients were not included in the study as metastatic spread would increase symptoms and make communication with the patient difficult), * Not receiving treatment for another cancer, * Not having a physical disability that would prevent telephone interviews (hearing, speech), * Not having any psychiatric disorder that would impair comprehension and understanding, * Patients who have verbally and in writing consented to participate in the study will be included in the research. Exclusion Criteria: * Patients with communication problems • Patients with psychiatric problems
Conditions Cardiovascular Biomarkers, Preeclampsia ...
Phase Not Applicable
Enrollment 172
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to find and confirm blood-based markers (called proteins) that may show early heart changes in women with preeclampsia, even before symptoms appear. It will also use heart ultrasound (echocardiography) to look at patterns of how the heart changes during pregnancy in women with preeclampsia. The main questions it aims to answer are: * Do these blood markers relate to heart changes on ultrasound? * How may they help predict future health problems for the mother? Participants will: * Complete a 20-minute survey that will include taking your baseline demographic information, clinical information/medical history, asking about pre-existing health conditions, including measuring your height, weight, and blood pressure. * Have transthoracic echocardiography (TTE) performed at 12 - 16 weeks gestation and again at 28 - 32 weeks gestation. * Provide a blood sample for these protein measurements. These samples will be collected at intake (12 - 16 weeks gestation) and again at 28 - 32 weeks gestation.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No Intervention: Observational Cohort — This is an observational study, and there is no intervention.

Primary Outcomes

  • Proteomic markers and cardiac-preE phenotypes (At 12-16 weeks gestation and at 28-32 weeks gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-24
Completion: 2027-12
Eligibility
Age: 13 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 172 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Collaborators: Vanderbilt University Medical Center, University of Abuja Teaching Hospital
Contact Information
Study Contact:
Zainab Mahmoud, MD, MSc
314-415-0009
zmahmoud@wustl.edu
Cecilia Nartey, MBChB, MPH
314-528-1082
c.nartey@wustl.edu
Dike Ojji, MBBS, PhD
234-806-009-4456
dike.ojji@uniabuja.edu.ng
University of Abuja Teaching Hospital
Interventions
  • Other: No Intervention: Observational Cohort — This is an observational study, and there is no intervention.
Study Locations (1 sites)
University of Abuja Teaching Hospital, Abuja, Nigeria
Eligibility Criteria
Inclusion Criteria: * • Pregnant women who are up to 20 weeks pregnant * Able to consent to participate in the study * Are enrolled in the ENHANCE-CVH study * Willing to undergo echocardiography and blood draws Exclusion Criteria: * • Known cardiac disease (e.g., cardiomyopathy, coronary artery disease \[CAD\]) * Sickle cell disease * Pulmonary arterial hypertension * Pulmonary embolism * Inability to provide informed consent * Acute Illness * Malignancy
Conditions Depression - Major Depressive Disorder, ...
Phase PHASE1
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1. Systematically categorize prohedonic effects (antianhedonic effects in patients with anhedonia in depression, increase in well-being in all participants). 2. Test effects of psilocybin on brain network complexity measures during the hedonic experience using fMRI as a correlate for prohedonic (anti-anhedonic and well-being increasing) effects. 3. Elucidate relevance of the psychedelic experience to these effects (clinical, behavioral, and imaging) in a pharmacological challenge using the 5-HT2A/D2 antagonist risperidone and extensive characterization of the psychedelic experience. Secondary Objectives 4. Test the differential effects of the psychedelic experience on fMRI paradigms measuring symptoms shown to be altered in anhedonia, more specifically reward processing and sexual arousal. 5. Test the relevance of neuroplasticity (BDNF) and inflammatory parameters to anti-anhedonic, well-being promoting, and brain network dynamic complexity effects. 6. Test the effects of the psychedelic experience on BDNF and inflammatory parameters. Researchers will compare the effects of psilocybin in two separate sessions (one with psilocybin alone, one with co-administration of risperidone) in both patients with depression and anhedonia and healthy control participants. Participants will: * Take 25 mg of psilocybin p.o. in two sessions, in one of the two sessions they will take 1 mg risperidone p.o. before ingestion of psilocybin, to block psilocybin's acute psychedelic effects. * Undergo 3 MRI sessions, one before the first psilocybin session ('baseline') and one session each on the day after each respective psilocybin session. * Perform a variety of tasks during each fMRI session to asses the treatment's effects on anhedonia.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin (Usona Institute) — Participants will recieve two doses of Psilocybin 25 mg to be taken orally over the course of the study.
  • Drug: Risperidone 1 MG — 30 minutes before administration of psilocybin in one of the sessions to inhibit acute psychedelic effects
  • Diagnostic Test: MRI — Over the course of the study, participants will undergo three MRI measurement sessions. * M1 (baseline, before treatment) * M2 \& M3 (one day after each psilocybin session)

Primary Outcomes

  • Aesthetic task (From enrolment until the second assessment session (up to 9 weeks after enrolment))
  • Monetary Incentive Delay (MID) Task (From enrolment until the last imaging session (up to 8 weeks after enrolment))
  • Sexual arousal task (From enrolment until the last imaging session (up to 8 weeks after enrolment))
  • Cognitive Flexibility Inventory (CFI) (From enrolment until the last follow-up session (expected at about 12 weeks after enrolment))
  • Intensity rating (From enrolment until the second medication session (up to 8 weeks after enrolment))
  • Warwick-Edinburgh Mental Well-being Scale (WEMWBS) (From enrolment until the last follow-up session (expected at about 12 weeks after enrolment))
  • Beck-Depression-Inventory (BDI) (From enrolment until the last follow-up session (expected at about 12 weeks after enrolment))
  • Montgomery-Åsberg Depression Rating Scale (MADRS) (From enrolment until the last follow-up session (expected at about 12 weeks after enrolment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-11-01
Completion: 2028-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Vienna
Collaborators: University of Vienna
Principal Investigators:
  • Marie Spies, Priv.-Doz. DDr. (PRINCIPAL_INVESTIGATOR) - Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry
Contact Information
Study Contact:
Marie Spies, Priv.-Doz. DDr.
+43 1 40400
marie.spies@meduniwien.ac.at
Clemens Schmidt, MD
+43 1 40400
clemens.schmidt@meduniwien.ac.at
Marie Spies, Priv.-Doz. DDr.
+43 1 40400
marie.spies@meduniwien.ac.at
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry
Interventions
  • Drug: Psilocybin (Usona Institute) — Participants will recieve two doses of Psilocybin 25 mg to be taken orally over the course of the study.
  • Drug: Risperidone 1 MG — 30 minutes before administration of psilocybin in one of the sessions to inhibit acute psychedelic effects
  • Diagnostic Test: MRI — Over the course of the study, participants will undergo three MRI measurement sessions. * M1 (baseline, before treatment) * M2 \& M3 (one day after each psilocybin session)
Study Locations (1 sites)
Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Vienna, State of Vienna 1160 Austria
Eligibility Criteria
Inclusion criteria: All participants: * General health based on medical history, physical examination, blood draw, and electrocardiogram * Age 18 to 55 years * Right-handedness (due to potential lateralization effects of left-handed subjects) * Willingness and competence to sign the informed consent form * Normal BMI weight range (18.5-24.9) Specific to healthy subjects: * Psychiatric health based on structured clinical interview for DSM-5 (SCID) * No concomitant medication Specific to anhedonia patients: * Major depressive episode (first or recurrent) based on structured clinical interview for DSM-5 (SCID) and ICD-10 * Fulfilling the ICD-10 diagnostic criterion of anhedonia * No concomitant medication, specifically also free of antidepressants or other psychopharmaceuticals (for at least 2 weeks, 5 weeks for fluoxetin) Exclusion criteria: All participants: * Current or history of neurological disease * Current medical illness requiring treatment * Pregnancy or current breastfeeding * Current or former substance dependency * Any contraindication for MRI * Failure to comply with the study protocol or to follow the instruction of the investigating team * Failure to confirm effective use of contraception in females at least 8 weeks before and after study participation each * First-degree relative with bipolar disorder or schizophrenia Specific to healthy subjects: \- Psychiatric diagnosis Specific to anhedonia patients: \- Psychiatric comorbidities excluding anxiety disorders and/or obsessive-compulsive disorders
Conditions Breast Cancer - Ductal Carcinoma in Situ...
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This single-center prospective study will evaluate the feasibility and safety of endoscopic nipple-sparing mastectomy (E-NSM) performed through a single axillary incision in selected women with breast cancer undergoing direct-to-implant breast reconstruction. The study will assess procedural feasibility, completeness of resection, short-term postoperative complications, and patient-reported outcomes

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic Nipple-Sparing Mastectomy (E-NSM) — Endoscopic nipple-sparing mastectomy performed through a single extra-mammary axillary incision using a standardized minimally invasive surgical technique; immediate direct-to-implant reconstruction will be performed according to institutional practice.

Primary Outcomes

  • Successful completion of endoscopic nipple-sparing mastectomy without conversion to open surgery (During the index surgical procedure)
  • Total operative time (During the index surgical procedure)
  • Negative surgical margin rate (From surgery to final pathology assessment, up to 30 days after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-11
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione del Piemonte per l'Oncologia
Contact Information
Study Contact:
Antonio Toesca, MD
0119933628
antonio.toesca@ircc.it
Giada Pozzi, MD
0119933676
giada.pozzi@ircc.it
Antonio Toesca, MD
0119933628
antonio.toesca@ircc.it
Breast Unit
Interventions
  • Procedure: Endoscopic Nipple-Sparing Mastectomy (E-NSM) — Endoscopic nipple-sparing mastectomy performed through a single extra-mammary axillary incision using a standardized minimally invasive surgical technique; immediate direct-to-implant reconstruction will be performed according to institutional practice.
Study Locations (1 sites)
Breast Unit, Candiolo, Turin 10060 Italy
Eligibility Criteria
Inclusion Criteria: * Female participants aged 18 years or older. * Diagnosis of early-stage invasive breast cancer or ductal carcinoma in situ, including multifocal or multicentric disease. * Candidate for nipple-sparing mastectomy with immediate direct-to-implant reconstruction. * Small- to medium-sized breasts with ptosis grade 2 or less. * Written informed consent provided. Exclusion Criteria: * Preoperative evidence of skin involvement, nipple-areola complex involvement, lymph-node metastases, inflammatory breast cancer, Paget's disease, mesenchymal breast tumors, or recurrent breast cancer. * Previous ipsilateral breast surgery. * Previous thoracic radiation therapy. * Heavy smoking (\>20 cigarettes/day), uncontrolled diabetes mellitus, or body mass index \>30. * ASA score 3 or higher. * Ongoing pregnancy
Conditions Acute Myocardial Infarction, Subclinical...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an exploratory, prospective, non-profit study (SUBDIMA) designed to investigate the prevalence and potential prognostic significance of subclinical depression in patients admitted with a first acute myocardial infarction (AMI). Subclinical depression refers to the presence of mild depressive symptoms (PHQ-9 score 5-9) that do not meet DSM-5 TR criteria for major depressive disorder but may still be clinically relevant. The primary aim is to estimate the prevalence of subclinical depression in this setting. Secondary, exploratory objectives include evaluating associations with inflammatory and metabolic biomarkers, autonomic dysfunction, cardiac function, cognitive performance, quality of life, treatment adherence, and the risk of recurrent cardiovascular events over 12 months. The study is expected to generate new descriptive data that may inform future confirmatory trials and support early, personalized approaches to integrated cardiac and mental health care.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Psychological, Cognitive, and Patient-Reported Outcome Assessments — Structured evaluation including PHQ-9, BDI-II, HAM-A, cognitive tests (CVLT-2, Matrici Attentive, Rey-Osterrieth), and validated questionnaires (EQ-5D-5L, PSQI, IPAQ, Medi-Lite, MARS-5) administered at baseline and during follow-up (3, 6, 9, and 12 months).

Primary Outcomes

  • Prevalence of Subclinical Depression in Patients with First Acute Myocardial Infarction (Baseline (hospital admission))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-14
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Principal Investigators:
  • Fabio Infusino (PRINCIPAL_INVESTIGATOR) - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  • Federica Mammarella, MD, PhD (STUDY_DIRECTOR) - Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Information
Study Contact:
Fabio Infusino, MD, PhD
+390630154187
fabio.infusino@policlinicogemelli.it
Federica Mammarella, MD, PhD
+390630154187
federica.mammarella@policlinicogemelli.it
Fabio Infusino
+390630155701
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Cardiologia
Interventions
  • Other: Psychological, Cognitive, and Patient-Reported Outcome Assessments — Structured evaluation including PHQ-9, BDI-II, HAM-A, cognitive tests (CVLT-2, Matrici Attentive, Rey-Osterrieth), and validated questionnaires (EQ-5D-5L, PSQI, IPAQ, Medi-Lite, MARS-5) administered at baseline and during follow-up (3, 6, 9, and 12 months).
Study Locations (1 sites)
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Cardiologia, Roma, Italia 00168 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Hospital admission for first acute myocardial infarction (STEMI or NSTEMI) within 7 days from the index event * PHQ-9 administered at screening * Mini Mental State Examination (MMSE) score ≥26 * Written informed consent obtained Exclusion Criteria: * Previous history of acute myocardial infarction * Diagnosis of major depression according to DSM-5 TR criteria * Severe cognitive impairment (MMSE \<26) * Severe comorbidities with expected survival \<12 months * Inability to participate in scheduled follow-up assessments * Refusal or inability to provide informed consent * Concurrent participation in other interventional clinical studies that could interfere with study outcomes
Conditions Morbid Obesity
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about how weight loss surgery (also called bariatric surgery) affects sexual function and sex hormone levels in women with severe obesity. It will also look at how the surgery affects mood, quality of life, body image, and the partner's sexual health. The main questions it aims to answer are: * Does sexual function improve after weight loss surgery? * Do sex hormone levels change after weight loss surgery? * Are these changes linked to improvements in mood and quality of life? * Does the partner also experience changes in sexual function? Researchers will compare each participant's results before surgery to their results 6 months after surgery. This helps show how things change over time. This study will include about 40 women who: * Are between 18 and 45 years old * Have severe obesity and are scheduled for weight loss surgery at Cairo University Hospital * Have a stable, sexually active partner relationship What participants will do: * Complete questionnaires about sexual function, mood, quality of life, and body image (twice: before surgery and 6 months after) * Provide a blood sample to measure sex hormone levels (before surgery and 6 months after) * Their partners will complete a short questionnaire about their own sexual function This research is important because sexual health is a key part of quality of life that is often overlooked in obesity care. Understanding how weight loss surgery affects sexual function, hormones, and mood can help doctors better counsel patients about what to expect after surgery. This is one of the first studies in Egypt to examine these questions and the first to include partner assessment. The study will start in January 2026. Results will be available by late 2026.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Sleeve Gastrectomy — Laparoscopic sleeve gastrectomy involves resection of approximately 80% of the stomach, creating a tubular gastric pouch. This restrictive procedure reduces gastric capacity and alters gut hormones.
  • Procedure: Gastric Bypass — Laparoscopic gastric bypass creates a small gastric pouch (15-30 mL) that is anastomosed to the jejunum, bypassing the remainder of the stomach and proximal small intestine. This combined restrictive and malabsorptive procedure produces significant weight loss and metabolic improvements.

Primary Outcomes

  • Change in Female Sexual Function (Baseline and 6 months post-operative)
  • Change in Sex Hormone Levels (Baseline and 6 months post-operative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-05
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Contact Information
Study Contact:
Ahmed Eid Aziz, Lecturer
+201127060844
Ahmed-eid@kasralainy.edu.eg
Mahmoud El Azhary, Lecturer
+201064110221
Mahmoud.azhary@kasralainy.edu.eg
Faculty of Medicine Cairo University
Interventions
  • Procedure: Sleeve Gastrectomy — Laparoscopic sleeve gastrectomy involves resection of approximately 80% of the stomach, creating a tubular gastric pouch. This restrictive procedure reduces gastric capacity and alters gut hormones.
  • Procedure: Gastric Bypass — Laparoscopic gastric bypass creates a small gastric pouch (15-30 mL) that is anastomosed to the jejunum, bypassing the remainder of the stomach and proximal small intestine. This combined restrictive and malabsorptive procedure produces significant weight loss and metabolic improvements.
Study Locations (1 sites)
Faculty of Medicine Cairo University, Cairo, Al-Manial Cairo 11956 Egypt
Eligibility Criteria
Inclusion Criteria: * Female gender * Age 18-45 years (childbearing period) * Body Mass Index (BMI) ≥40 kg/m² or ≥35 kg/m² with obesity-related comorbidities, meeting international criteria for bariatric surgery * Scheduled for primary bariatric surgery (sleeve gastrectomy or Roux-en-Y gastric bypass) * Presence of a stable, sexually active intimate partner relationship * Sexually active * Willingness to participate and provide informed consent * Ability to complete Arabic-language questionnaires Exclusion Criteria: * Women who are not sexually active * Post-menopausal women (amenorrhea ≥12 months without other cause) * Current pregnancy or lactation * History of medication use that can interfere with sexual function, including: * Antidepressants * Antipsychotics/psychotropic drugs * Beta-blockers * Spironolactone * Hormonal contraceptives (unless stable for ≥3 months and continued throughout study) * Hormone replacement therapy * Major uncontrolled medical conditions: * Chronic heavy smoker (smoking index ≥400 pack-years) * History of pelvic floor surgery or gynecological malignancy * Partner with known erectile dysfunction or use of erectile dysfunction medications * Previous bariatric surgery (revisional procedures) * Inability or unwillingness to provide informed consent
Conditions Breast Carcinoma, Breast Cancer
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study compares measurements of body composition to outcomes of breast reconstruction.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Measurement of Body Composition — Body composition measurements collected pre and post operatively using a bioelectrical impedance analyzer.
  • Other: Chart Review — Clinical and surgical data will be collected from the participants medical records.

Primary Outcomes

  • Proportion of Body Composition Measurement Collection (up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-18
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Principal Investigators:
  • Merisas Piper, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Michael Choi
877-827-3222
Michael.Choi@ucsf.edu
Michael Choi
877-827-3222
Michael.Choi@ucsf.edu
University of California
877-827-3222
cancertrials@ucsf.edu
University of California
Interventions
  • Procedure: Measurement of Body Composition — Body composition measurements collected pre and post operatively using a bioelectrical impedance analyzer.
  • Other: Chart Review — Clinical and surgical data will be collected from the participants medical records.
Study Locations (1 sites)
University of California, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: 1. Patients must have histologically confirmed breast malignancy or increased risk of developing a breast malignancy. 2. Age ≥ 18 years. 3. Scheduled to undergo mastectomy with immediate breast reconstruction using a permanent implant, tissue expander, or autologous tissue (e.g. Deep Inferior Epigastric Perforator (DIEP) flap, muscle-sparing Transverse Rectus Abdominis Myocutaneous (msTRAM) flap, Profunda Artery Perforator (PAP) flap). 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Any significant medical condition or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. 2. Pregnant or breastfeeding. 3. Patients assigned male at birth. 4. Non-cisgender women. 5. Patients with implanted electronic medical devices (e.g. pacemaker, defibrillator). 6. Patients with prosthetic limbs.
Conditions Type 2 Diabetes, Diabetes With Diabetic ...
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate whether a class of diabetes medications called GLP-1 receptor agonists (GLP-1RA), specifically semaglutide or polyethylene glycol loxenatide, can improve heart-related nerve damage in people with type 2 diabetes. This heart-related nerve damage is known as diabetic cardiac autonomic neuropathy (DCAN), which can cause problems such as fast resting heart rate, low blood pressure upon standing, and in severe cases, heart attack or sudden death. In this study, 60 adults with type 2 diabetes (ages 18-80) will be randomly divided into two groups. One group will receive standard diabetes care only, while the other group will receive standard care plus a once-weekly injection of either semaglutide or polyethylene glycol loxenatide for 6 months. Participants will undergo tests before and after the treatment period, including blood tests and non-invasive heart function tests (24-hour heart rate variability monitoring and cardiac autonomic reflex tests). The main goal is to see whether GLP-1RA treatment improves heart rate variability, a key sign of heart nerve function. The study also looks at changes in body weight, blood sugar control, and insulin resistance. This research may help determine whether GLP-1RA medications can protect against or improve diabetic heart nerve damage, beyond their known benefits for blood sugar control.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GLP-1 Receptor Agonists — GLP-1 receptor agonists are administered as a once-weekly subcutaneous injection for 6 months. Two specific GLP-1RAs are used in this study: semaglutide at 0.5 mg once weekly, or polyethylene glycol loxenatide at 0.2 mg once weekly. Both are approved for the treatment of type 2 diabetes and are used within their approved dosing guidelines.

Primary Outcomes

  • heart rate variability(HRV) (baseline and 12 weeks later])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-04-01
Completion: 2028-08-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
jianbo Li
13115008178
ljbzjlx18@aliyun.com
jianbo Li, Principal Investigator
13115008178
ljbzjlx18@aliyun.com
the First Affiliated Hospital of Nanjing Medical University
Interventions
  • Drug: GLP-1 Receptor Agonists — GLP-1 receptor agonists are administered as a once-weekly subcutaneous injection for 6 months. Two specific GLP-1RAs are used in this study: semaglutide at 0.5 mg once weekly, or polyethylene glycol loxenatide at 0.2 mg once weekly. Both are approved for the treatment of type 2 diabetes and are used within their approved dosing guidelines.
Study Locations (1 sites)
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029 China
Eligibility Criteria
Inclusion Criteria: * Patients aged 18-70 years * Patients with type 2 diabetes mellitus (T2DM) who meet the diagnostic guidelines * Patient has signed the relevant informed consent form * Being overweight or obese (BMI ≥ 24 kg/m²) Exclusion Criteria: * Age \< 18 years * Pregnant or lactating women * Acute or chronic pancreatitis * Recent acute complications of diabetes (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state) * Arrhythmia or taking medications that affect heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, antiarrhythmic drugs) * Thyroid disease * Severe organ dysfunction (e.g., heart, liver, kidney failure) * Denial of informed consent
Conditions Perinatal Anxiety, Anxiety Sensitivity, ...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to find out if a digital program called Reaching Calm can help prevent anxiety in women who are pregnant. The study will offer Reaching Calm at obstetric practices where participants receive prenatal care. The study focuses on people who may be at greater risk for experiencing anxiety during or after pregnancy. The main questions this study aims to answer are: * Is Reaching Calm easy to use and acceptable to both participants and healthcare professionals? * Does Reaching Calm help reduce risk for anxiety among participants? * Does personalizing the digital program help participants stay involved? Researchers will compare obstetric practices that offer Reaching Calm to those providing usual care. Participants will: * Receive text messages and use a web-based platform for learning about anxiety and coping strategies * Respond to surveys about their experiences and symptoms * Some will take part in interviews and focus groups to share their views * Healthcare professionals will receive training on how to support the program The study will monitor how many people join, stay involved, and how the program affects their well-being. The results will help prepare for a larger study that could lead to wider use of Reaching Calm across the country.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Digital mental health intervention — Reaching Calm is a digital intervention designed to prevent anxiety in pregnant patients. It includes: (1) a digital Anxiety Sensitivity Intervention delivered via text messages and web-based psychoeducation and exposure exercises; (2) training for obstetric (OB) professionals to support anxiety prevention and program integration; and (3) an implementation protocol that adapts workflows to make Reaching Calm accessible during routine OB care. The intervention uses personalized content and resources based on participant feedback.

Primary Outcomes

  • Generalized Anxiety Disorder-7 (GAD-7) scale (Baseline, 4-weeks, and 8 weeks)
  • Anxiety Sensitivity Index-3 (ASI-3) (Baseline, 4 weeks, 8 weeks)
  • Treatment Evaluation Inventory Short Form (TEI-SF) (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-15
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Collaborators: National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Martha Zimmermann, PhD
617-870-4798
martha.zimmermann1@umassmed.edu
Reaching Calm Study Team
978-732-4583
RCAppStudy@umassmed.edu
Carolyn Friedhoff Alvarez
UMass Memorial Medical Group - Montachusett Women's Health
Interventions
  • Behavioral: Digital mental health intervention — Reaching Calm is a digital intervention designed to prevent anxiety in pregnant patients. It includes: (1) a digital Anxiety Sensitivity Intervention delivered via text messages and web-based psychoeducation and exposure exercises; (2) training for obstetric (OB) professionals to support anxiety prevention and program integration; and (3) an implementation protocol that adapts workflows to make Reaching Calm accessible during routine OB care. The intervention uses personalized content and resources based on participant feedback.
Study Locations (1 sites)
UMass Memorial Medical Group - Montachusett Women's Health, Leominster, Massachusetts 01453 United States
Eligibility Criteria
Inclusion Criteria: * Receiving prenatal care at participating obstetric practice * Endorsed mild to moderate anxiety (GAD-7 score 5-15) * Currently pregnant (gestational age \<32) * Started Reaching Calm digital intervention, if in intervention group Exclusion Criteria: * Not pregnant * Unable to participate in 60-minute interview * Unwilling to be audio recorded * GAD-7 \<5, or GAD-7≥15 * Adults unable to consent (adults lacking capacity) * Individuals who are not yet adults (infants, children, teenagers) * Prisoners * Non-English-speaking
Conditions Gastric or Gastro-esophageal Junction (G...
Phase PHASE1, PHASE2
Enrollment 150
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion. In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C. In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C. People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ASP546C — Intravenous administration

Primary Outcomes

  • Part 1: Objective Response Rate (ORR) per Investigator-assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to 36 Months)
  • Part 1: Pharmacokinetics (PK) of ASP546C Antibody-drug Conjugate (ADC): Serum Concentrations of Antibody-drug Conjugate (Up to 39 Months)
  • Part 1: PK of ASP546C ADC: Maximum Concentration (Cmax) (Up to 39 Months)
  • Part 1: PK of ASP546C ADC: Area Under the Serum Concentration-time Curve from Time Zero to 21Days (AUC0-21d) (Up to 39 Months)
  • Part 1: Number of participants with Adverse events (AEs) (Up to 39 Months)
  • Part 1: Number of Participants with Vital Sign Abnormalities and/or AEs (Up to 39 Months)
  • Part 1: Number of Participants with Laboratory Value Abnormalities and/or AEs (Up to 39 Months)
  • Part 1: Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status Scores (Up to 39 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-05-04
Completion: 2029-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Astellas Pharma Global Development, Inc.
Principal Investigators:
  • Study Physician (STUDY_DIRECTOR) - Astellas Pharma Global Development, Inc.
Contact Information
Study Contact:
Astellas Pharma Global Development, Inc
800-888-7704
Astellas.registration@astellas.com
Interventions
  • Drug: ASP546C — Intravenous administration
Study Locations (21 sites)
UAB Medicine - UAB Hospital, Birmingham, Alabama 35249 United States
START Los Angeles, Los Angeles, California 90025 United States
Miami Cancer Institute, Miami, Florida 33176 United States
Winship Cancer Institute at Emory University, Atlanta, Georgia 30322 United States
Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis, Indiana 46202 United States
Barbara Ann Karmanos Cancer Center, Detroit, Michigan 48201 United States
START Midwest, Grand Rapids, Michigan 49546 United States
Hackensack University Medical Center, Hackensack, New Jersey 07601 United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States
START New York, Lake Success, New York 10042 United States
Eligibility Criteria
Inclusion Criteria: * Participant has a histologically confirmed diagnosis of gastroesophageal (gastric/GEJ/esophageal) adenocarcinoma, pancreatic adenocarcinoma, or pan-tumor (cholangiocarcinoma, colorectal adenocarcinoma, NSCLC \[adenocarcinoma\], SCLC, ovarian mucinous carcinoma or invasive breast cancer \[ER/PR+HER2-; ER/PR-HER2+; ER/PR+HER2+ (triple positive); ER/PR-HER2- (triple negative)\]. * Participant has radiologically confirmed uLA/m gastroesophageal (gastric/GEJ/esophageal) adenocarcinoma, pancreatic adenocarcinoma or pan-tumor within 28 days prior to the first dose of study intervention. * Cohorts 1 to 3 only: Participant has measurable disease according to RECIST v1.1 within 28 days prior to the first dose of study intervention. For participants with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. * Cohort 4 only: Participant has radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, within 28 days prior to the first dose of study intervention. For participants with only 1 evaluable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. * Participant's tumor expresses CLDN18.2. * Participant has received at least 1 line of therapy for uLA/m disease. * Participant has an ECOG performance status of 0 or 1. * Participant has a predicted life expectancy \>= 12 weeks. * Female participant is not pregnant and at least 1 of the following conditions apply: * Not a women of childbearing potential (WOCBP) * WOCBP who has a negative urine or serum pregnancy test at screening (Specific to Japan: with a medical interview), and agrees to follow the contraceptive guidance from the time of informed consent through at least 5 half-lives (45 days) plus 6 months after final investigational study intervention administration. * Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (45 days) plus 6 months after final investigational study intervention administration. * Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period and for 5 half-lives (45 days) plus 6 months after final investigational study intervention administration. * Male participant must agree to use contraception with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration. * Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration. * Male participant must not donate sperm during the treatment period and for 5 half-lives (45 days) plus 3 months after final investigational study intervention administration. * Participant must meet all of the criteria based on the locally analyzed laboratory tests collected within 14 days prior to the first dose of study intervention. In case of multiple local laboratory tests within this period, the most recent data should be used. * Participant is willing to provide or has sufficient tumor tissue for central biomarker assessment. * Participant agrees not to participate in another interventional study while receiving study intervention in the present study. Exclusion Criteria: * Cohorts 1, 2 and 3 only: Participant's disease is of the non-adenocarcinoma histology or mixed histology containing adenocarcinoma. * Cohorts 1, 2 and 3 only: Participant has received \> 2 prior lines of therapy for uLA/m disease. * Participants in Cohort 4 (pan-tumor) may enroll regardless of the number of prior lines of therapy, if they are not eligible for, decline, or do not have any available standard of care treatment options. * Participant has complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent recurrent vomiting. * Participant has significant gastric bleeding or had a significant bleeding episode from the gastrointestinal tract within 3 months prior to the first dose of study intervention and/or an untreated peptic ulcer disease that would preclude the participant from participation. * Participant has significant bleeding disorders or has had vasculitis within 3 months prior to the first dose of study intervention. * Participant has a history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of study intervention. * Participant has symptomatic, untreated brain metastases or meningeal carcinomatosis (carcinomatous meningitis) from the primary malignancy. A participant with stable central nervous system metastases for \> 3 months without need of steroids for \>= 2 weeks prior to the first dose of study intervention is eligible. * Participant has a past or current mental illness that is difficult to control. * Participant has unresolved pneumonitis or a history of non-infectious pneumonitis such as immune-related pneumonitis or radiation-induced pneumonitis for which the participant is taking glucocorticoids or needed glucocorticoids within 6 months prior to the first dose of study intervention. * Participant has a known history of a positive test for human immunodeficiency virus (HIV) infection or known active hepatitis B (positive hepatitis B surface antigen \[HBsAg\]) or hepatitis C infection. Screening for these infections should be conducted if indicated per local requirements. * If participant is negative for HBsAg, but hepatitis B core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) positive, a hepatitis B DNA test will be performed; if the test is positive, the participant will be excluded. * Participant with positive hepatitis C virus (HCV) serology, but negative HCV RNA test results, is eligible. * Participant treated for HCV with undetectable viral load results is eligible. * Participant has an active infection requiring systemic therapy that has not completely resolved within 7 days prior to the first dose of study intervention. * Participant has a malignancy for which treatment is required, has a history of another malignancy within the past 5 years, except malignancies for which participant received curative therapy without recurrence for the last 5 years (e.g., adequately resected non-melanoma skin cancer, localized prostate cancer), or had treatment for carcinoma in situ. * Participant has clinically significant third spacing (large amount of pleural fluid or ascites) that requires frequent percutaneous draining or requires placement of a drainage catheter for adequate control. * Participant has any AE from prior antitumor treatments that has not yet recovered to grade 0 or 1 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0 (except alopecia). * Participant has an active autoimmune disease or other medical condition that has required high dose systemic steroids at the time of screening. * Participant has known peripheral neuropathy \> grade 1 (except when the sole neurological abnormality is absence of deep tendon reflexes). * Participant has sinusoidal obstruction syndrome, formerly known as veno-occlusive disease; if present, should be stable or improving. * Participant has significant cardiovascular disease, including any of the following: * Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to the first dose of st